D. Toth

A prospective phase III, randomized, double‐blind, placebo‐controlled study of brodalumab in patients with moderate‐to‐severe plaque psoriasis

Kim Papp, Kristian Reich, C. Paul et al. · British Journal of Dermatology · 2016 · 459 citations

Medicine, Dermatology, Pharmacotherapy +13

Tralokinumab plus topical corticosteroids for the treatment of moderate‐to‐severe atopic dermatitis: results from the double‐blind, randomized, multicentre, placebo‐controlled phase III ECZTRA 3 trial*

Jonathan I. Silverberg, D. Toth, Thomas Bieber et al. · British Journal of Dermatology · 2020 · 317 citations · Full text

Medicine, Dermatology, Immunology +17

Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate‐to‐severe psoriasis through 5 years of treatment (<scp>SCULPTURE</scp> Extension Study)

Robert Bissonnette, Thomas A. Luger, Diamant Thaçi et al. · Journal of the European Academy of Dermatology and Venereology · 2018 · 193 citations · Full text

Medicine, Dermatology, Pharmacotherapy +16

Secukinumab sustains good efficacy and favourable safety in moderate-to-severe psoriasis after up to 3 years of treatment: results from a double-blind extension study

Robert Bissonnette, Thomas A. Luger, Diamant Thaçi et al. · British Journal of Dermatology · 2017 · 69 citations

Pharmacy, Pharmacology, Pharmacotherapy +10

208 Long-Term Safety and Disease Control With Ruxolitinib Cream in Atopic Dermatitis: Results From Two Phase 3 Studies

Kim Papp, Jacek C. Szepietowski, Leon Kircik et al. · Journal of Investigative Dermatology · 2021 · 13 citations

Medicine, Dermatology, Pharmacotherapy +12